Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13 - Université de Lorraine Access content directly
Journal Articles Expert Opinion on Biological Therapy Year : 2021

Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13

Abstract

Biologic drugs have significantly improved the treatment of ulcerative colitis (UC) and Crohn's disease (CD). However, the availability of these drugs is limited by their high cost. Infliximab was the first biologic to be approved for inflammatory bowel diseases (IBD). After its patent expired other manufactures developed biosimilar versions, among which CT-P13, and licensed them thorough an expedite process.
No file

Dates and versions

hal-04214645 , version 1 (22-09-2023)

Identifiers

Cite

Tommaso Lorenzo Parigi, Ferdinando d'Amico, Laurent Peyrin-Biroulet, Silvio Danese. Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13. Expert Opinion on Biological Therapy, 2021, 21 (1), pp.37-46. ⟨10.1080/14712598.2020.1811849⟩. ⟨hal-04214645⟩
10 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More